Loading…
Sanofi is projected to rise to $54.08 by 2027, a +22% move from its current price of $44.43. SNY is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $43.93 | $44.44 | $44.96 | +0.02% |
| May 30 | $43.73 | $44.45 | $45.19 | +0.05% |
| May 31 | $43.58 | $44.46 | $45.36 | +0.07% |
| Jun 1 | $43.46 | $44.47 | $45.52 | +0.10% |
| Jun 2 | $43.35 | $44.49 | $45.65 | +0.12% |
| Jun 3 | $43.25 | $44.50 | $45.78 | +0.15% |
| Jun 4 | $43.16 | $44.51 | $45.89 | +0.17% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $43.16 | $44.51 | $45.89 | +0.17% |
| Week 2 | $42.70 | $44.58 | $46.56 | +0.35% |
| Week 3 | $42.36 | $44.66 | $47.10 | +0.52% |
| Week 4 | $42.08 | $44.74 | $47.57 | +0.70% |
| Week 5 | $41.85 | $44.82 | $47.99 | +0.87% |
| Week 6 | $41.65 | $44.90 | $48.39 | +1.05% |
| Week 7 | $41.47 | $44.97 | $48.77 | +1.22% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines.
It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc.
to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc.
for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc.
for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Sanofi (SNY) is a healthcare company with a market capitalization of $105.85B and a current price of $44.29. It is ranked 148 by market position. The stock’s price outlook is bullish over the forecast horizon, with year-by-year targets showing a rising trajectory from 2026 through 2050.
The 2026 forecast average price is $44.29, with meaningful upside ahead in subsequent years.
A major floor 11.5% below — a decisive break under it would weaken the trend.
The nearest floor, 4.5% below — buyers have tended to step in here.
The nearest ceiling, 8.2% above — a clean break opens room to run.
A major ceiling 13.9% above — clearing it would confirm fresh momentum.
Key SNY support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SNY market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $44.49 | Sell | $44.25 | Buy |
| MA 10 | $43.75 | Buy | $44.07 | Buy |
| MA 20 | $43.93 | Buy | $44.30 | Buy |
| MA 50 | $45.56 | Sell | $45.19 | Sell |
| MA 100 | $46.20 | Sell | $46.11 | Sell |
| MA 200 | $47.62 | Sell | $47.34 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.06 | Neutral |
| Stoch RSI (14) | 85.74 | Sell |
| CCI (20) | 34.47 | Neutral |
| Williams %R (14) | -19.60 | Info |
| MACD (12,26,9) | 0.23 | Buy |
| ROC (12) | 2.59 | Buy |
| Bollinger %B (20,2) | 0.61 | Neutral |
| Stochastic %K (14) | 80.40 | Sell |
| TRIX (15) | -0.23 | Sell |
| Awesome (5,34) | -0.77 | Sell |
| Ultimate (7,14,28) | 65.03 | Neutral |
| Momentum (10) | 1.57 | Buy |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 44.69 | Sell |
| ADX (14) | 17.41 | Neutral |
| ATR (14) | 0.48 | Info |
In the near term, sentiment is neutral. The RSI14 sits at 50, suggesting balanced momentum, while the 50-day simple moving average is $45.54 and the 200-day simple moving average is $47.65. Immediate support is at $42.42 and resistance at $48.06, framing a 30-day range from $40.86 to $48.01.
Annualized volatility is about 20%, underscoring moderate price fluctuation within the month.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $42.42 | $44.43 | $58.29 | 0% | Neutral | |
| $44.18 | $54.08 | $69.30 | +22% | Bullish | |
| $51.01 | $63.58 | $83.59 | +43% | Bullish | |
| $57.35 | $72.56 | $97.39 | +63% | Bullish | |
| $58.96 | $75.60 | $103.26 | +70% | Bullish | |
| $60.65 | $78.71 | $109.18 | +77% | Bullish | |
| $64.57 | $84.72 | $119.18 | +91% | Bullish | |
| $68.52 | $90.85 | $129.43 | +104% | Bullish | |
| $81.98 | $109.77 | $158.24 | +147% | Bullish | |
| $89.20 | $120.57 | $175.72 | +171% | Bullish | |
| $117.51 | $165.63 | $252.90 | +273% | Bullish | |
| $200.54 | $303.10 | $495.96 | +582% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $42.42 | $44.43 | $51.85 | +0.00% |
| June 2026 | $37.82 | $44.11 | $52.46 | -0.71% |
| July 2026 | $38.74 | $45.45 | $54.56 | +3.02% |
| August 2026 | $39.21 | $46.21 | $55.87 | +1.68% |
| September 2026 | $38.76 | $45.86 | $55.78 | -0.77% |
| October 2026 | $39.20 | $46.53 | $56.91 | +1.48% |
| November 2026 | $40.08 | $47.71 | $58.62 | +2.54% |
| December 2026 | $39.56 | $47.23 | $58.29 | -1.00% |
Click any year to see its month-by-month SNY forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, SNY could reach as high as $58.29, with a base case around $44.43 and support toward $42.42 — roughly 0% from $44.43. A consolidation phase looks the most probable path here.
Expect SNY to range from $44.18 to $69.30 through 2027. The $54.08 average target implies a +22% move from current prices. That is up +22% on the projected 2026 average. Momentum favours further upside here.
The SNY price prediction for 2028 points to an average of $63.58 (low $51.01, high $83.59) — a potential gain of +43% on today's $44.43. Buyers look set to stay in control over this stretch.
In 2029, SNY is projected to trade between $57.35 and $97.39, averaging $72.56 — a potential gain of +63% from today's $44.43. That is up +14% on the projected 2028 average. Momentum favours further upside here.
Sanofi's 2030 outlook centres on $75.60, within a $58.96 to $103.26 range. That is up +4% on the projected 2029 average. That marks a +70% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, SNY could reach as high as $109.18, with a base case around $78.71 and support toward $60.65 — roughly +77% from $44.43. Momentum favours further upside here.
Expect SNY to range from $64.57 to $119.18 through 2032. The $84.72 average target implies a +91% move from current prices. That is up +8% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The SNY price prediction for 2033 points to an average of $90.85 (low $68.52, high $129.43) — a potential gain of +104% on today's $44.43. Momentum favours further upside here.
In 2034, SNY is projected to trade between $81.98 and $158.24, averaging $109.77 — a potential gain of +147% from today's $44.43. That is up +21% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Sanofi's 2035 outlook centres on $120.57, within a $89.20 to $175.72 range. That is up +10% on the projected 2034 average. That marks a +171% change versus current levels. Momentum favours further upside here.
By 2040, SNY could reach as high as $252.90, with a base case around $165.63 and support toward $117.51 — roughly +273% from $44.43. Buyers look set to stay in control over this stretch.
Expect SNY to range from $200.54 to $495.96 through 2050. The $303.10 average target implies a +582% move from current prices. That is up +83% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in SNY today (≈ 22.507315 SNY) could be worth
$6,822.05
+$5,822.05 (+582%) by 2050 · US Dollar
Based on the average projected SNY price of $303.1 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SNYwould be worth at today's price.
$1,000 invested in SNY on May 27, 2025 (≈ 19.087612 SNY) would be worth
$848.06
-$151.94 (-15.2%) today · 0.85× · US Dollar
Based on a SNY entry price of $52.39 vs. today's $44.43.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $44.67 | $994.63 | -0.5% |
| 1 month ago | $45.9 | $967.97 | -3.2% |
| 3 months ago | $48.35 | $918.92 | -8.1% |
| 6 months ago | $49.88 | $890.74 | -10.9% |
| 1 year ago | $52.39 | $848.06 | -15.2% |
| All time (5.0y) ago | $52.47 | $846.77 | -15.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SNY forecast.
Our base-case forecast reaches $89.00 around 2033.
Implied market cap at $89.00: $212.71B
Looking further out, the forecast shows a bullish trajectory with increasing average prices and rising ROI through 2030 and beyond. The 2030 forecast lists an average price of $76.07 with a 71.8% ROI and a bullish sentiment. The 2040 forecast indicates an average of $168.15 and a 279.7% ROI, still with bullish sentiment.
The 2050 forecast projects an average of $305.37 and a 589.5% ROI, continuing the bullish view. These milestones reflect an expected long-term appreciation, though these are estimates and not guarantees, and carry inherent market risk.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $76.07 with a 71.8% ROI and a bullish sentiment.
The 2026 forecast lists an average price of $44.29 (with a range from $42.42 to $57.98) and a neutral sentiment, with an ROI of 0%.
The 2031 forecast shows an average of $79.12 with a max of $109.77, indicating the potential to exceed $100 at the high end.
The 2050 forecast shows an average of $305.37 with a 589.5% ROI and bullish sentiment.
Current price is $44.29 and market cap is $105.85B.
Sanofi Community Discussion
0Share your Sanofi price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.